Article Text

Download PDFPDF
Nirsevimab reduces medically attended RSV-associated lower respiratory tract infection and hospitalisations in healthy pre-term infants
  1. Sarah Murphy
  1. Department of Paediatrics, Cork University Hospital, Cork, Ireland
  1. Correspondence to Dr Sarah Murphy, Paediatrics, Cork University Hospital, Cork, Ireland; sarah.murphy25{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Review of: Griffin MP, Yuan Y, Takas T, et al. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med 2020;383:415–25.

Study design: Randomised clinical trial.

Allocation and blinding: Nirsevimab: placebo, 2:1 ratio. Randomisation was stratified by hemisphere (northern or southern) and by age (≤3 months, >3 months to ≤6 months, or >6 months). Concealment was ensured by using an interactive web response system. Participants, carers and outcome observers were blinded to allocation.

Setting: Multisite international clinical trial including 23 countries from both the northern and southern hemispheres.

Patients: Healthy ex-premature (29 + 0 to 34 = 6 weeks) infants without current indication for palivizumab, and without bronchopulmonary dysplasia, liver, renal or cardiac impairment who were currently aged <1 year (8 months in EU) and entering their first bronchiolitis season.

Intervention: Nirsevimab 50 mg intramuscularly or matching placebo, given once, 2 months before RSV season.


Primary outcome: Clinically documented, PCR-proven, medically attended respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI).

Secondary outcome: Hospitalisation for RSV …

View Full Text


  • Contributors SM wrote the abstract and commentary.

  • Provenance and peer review Not commissioned; internally peer reviewed.